ADVENTRX Announces Completion Of Patient Enrollment In Phase 2 Clinical Trial Of CoFactor(R) For The Treatment Of Advanced Breast Cancer

ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced that it has completed patient enrollment in its Phase 2 clinical trial of ANX-510, or CoFactor, for the treatment of advanced breast cancer. [click link for full article]

More: continued here

Filed under: Breast Cancer on December 6th, 2007